About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cardiac Toxicity in Medical Treatment of Breast Cancer

NCT02440620·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Odense University Hospital

With

University of Southern Denmark

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of HER2 positive breast cancer
Adjuvant treatment with trastuzumab

You may not be if

Left ventricle ejection fraction (LVEF) \<50%
Chronic or persistent atrial fibrillation
History of moderate or severe valvular heart disease.

The record

StatusCompleted

PhaseNo phase

Taking part45

StartedOct 2014

UpdatedMay 1, 2019

Conditions

Heart Failure Breast Cancer

Where1

Odense University Hospital
Odense C, Denmark

Clareo Health | Cardiac Toxicity in Medical Treatment of Breast Cancer